Literature DB >> 3796829

Chronic nephrotoxicity complicating cyclosporine treatment of chronic inflammatory demyelinating polyradiculoneuropathy.

S Kolkin, N S Nahman, J R Mendell.   

Abstract

We elected to use cyclosporin A (CsA) in a woman debilitated by refractory chronic inflammatory demyelinating polyradiculoneuropathy. Although strength improved coincident with CsA therapy, after 21 months she developed congestive heart failure and had a precipitous loss of renal function with chronic renal failure requiring hemodialysis. While most CsA-induced nephrotoxicity is dose related and reversible, the kidney biopsy in our patient showed chronic nephropathy, a complication previously unreported in the native kidney of a nontransplant patient. A slow rise in blood pressure preceded serum creatinine changes and was an early indicator of impending irreversible nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3796829     DOI: 10.1212/wnl.37.1.147

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Treatment of chronic relapsing inflammatory demyelinating polyneuropathy by cyclosporin A and plasma exchange. A case report.

Authors:  H Hefter; K B Sprenger; G Arendt; D Hafner
Journal:  J Neurol       Date:  1990-08       Impact factor: 4.849

2.  Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A.

Authors:  W Mahattanakul; T O Crawford; J W Griffin; J M Goldstein; D R Cornblath
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-02       Impact factor: 10.154

Review 3.  Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Mohamed Mahdi-Rogers; Ruth Brassington; Angela A Gunn; Pieter A van Doorn; Richard Ac Hughes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

4.  Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy.

Authors:  S J Hodgkinson; J D Pollard; J G McLeod
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.